A Phase 2/3 interventional study of Continuous Positive Airway Pressure (CPAP) in Breast Cancer Early Stage Breast Cancer (Stage 1-3), sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to female participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-28.
Sponsored by Universitaire Ziekenhuizen KU Leuven · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven — 7 open to participants now, 8 under way, 1 of them phase 3. Breast Neoplasms · Universitaire Ziekenhuizen KU Leuven.
Among the 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven, this one is the 16th largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 2/3, and was the 30th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →7 of the 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven are open now, in 1 country. Recruiting first, the newest first:
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18–100 · Women only
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 40 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 2
First in 2005; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 53 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 21 interventional studies, 69 across the 10 observational. Of the 20 that completed or were terminated, 3 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 965 studies on the registry; 268 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07373782Phase 3Universitaire Ziekenhuizen KU LeuvenContinuous Positive Airway Pressure (CPAP) Assisted Radiotherapy in Breast Cancer | 2026-12 |
| NCT06415032Universitaire Ziekenhuizen KU LeuvenQuilting Sutures After Mastectomy | 2027-04 |
| NCT06324721Universitaire Ziekenhuizen KU LeuvenWho and Why do Patients Report Lymphedema After Breast Cancer Treatment Without an Objective Measurable Swelling | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a prospective, non-randomized clinical study aimed at investigating the potential benefits of continuous positive airway pressure (CPAP) support during radiotherapy for breast cancer. CPAP is a device commonly used to support breathing, for example in patients with sleep apnea. The investigators expect a reduction in radiation doses to the heart and/or lungs with CPAP-supported radiotherapy compared to standard radiotherapy (without CPAP), which may also lead to a decrease in radiation-induced heart and/or lung conditions in the long term. The study will also examine how the use of a CPAP device can be implemented in daily radiotherapy practice.
Patients undergoing breast conserving surgery for invasive or in situ BC and requiring adjuvant RT are prospectively enrolled -either left-sided cases with or without regional nodal irradiation (RNI), or right-sided cases requiring RNI. Each patient undergoes an additional CT simulation with continuous positive airway pressure (CPAP) (15cm H20) -in free breathing (FB) for right-sided cases and in deep inspiration breath hold (DIBH) for left-sided cases. Left-sided patients unable to perform DIBH are evaluated in FB. Two RT plans (with and without CPAP) are dosimetrically compared. If CPAP reduces mean heart or CLB dose by ≥0.5 Gy, or mean lung dose by ≥1 Gy, treatment is delivered with CPAP. Patient comfort is assessed through surveys.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CPAP is added to standard of care
Device: Continuous Positive Airway Pressure (CPAP)
Right sided or 70 years or older: Free Breathing Left sided and younger than 70 years old: Deep Inspiration Breath Hold
Positive airway pressure (15cmH2O) delivered by a CPAP-device
Mean heart dose
Potential change of mean radiation dose to the heart
Time frame: From enrollment to the end of treatment at +/-8 weeks
Doses to cardiac substructures
Potential change in radiation dose to cardiac substructures
Time frame: From enrollment to the end of treatment at +/-8 weeks
Mean lung dose
Potential change in mean radiation dose to the lungs
Time frame: From enrollment to the end of treatment at +/-8 weeks
Mean contralateral breast dose
Potential change in mean radiation dose to the contralateral breast
Time frame: From enrollment to the end of treatment at +/-8 weeks
Liver dose
Potential change in radiation dose to the liver
Time frame: From enrollment to the end of treatment at +/-8 weeks
Patient comfort
Patient comfort assessed through patient questionnaires (Likert scale: Strongly disagree - disagree - neutral - agree - strongly agree)
Time frame: From enrollment to the end of treatment at +/-8 weeks
Reproducibility and accuracy of CPAP-assisted radiotherapy
Compare reproducibility and accuracy between standard and CPAP-assisted RT by using surface scanning and daily cone beam CT (CBCT) parameters
Time frame: From enrollment to the end of treatment at +/-8 weeks
DIBH performance
To compare DIBH performance between standard and CPAP-assisted RT for left-sided BC by using surface scanning and daily CBCT parameters
Time frame: From enrollment to the end of treatment at +/-8 weeks
Time-effectiveness
To compare time-effectiveness between standard and CPAP-assisted RT * Set-up time * Matching time * Radiation time
Time frame: From enrollment to the end of treatment at +/-8 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.
Of 43 non-industry phase 2/3 interventional studies under Breast Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 91. This study's planned 22 months is below that.
Counting every sponsor, half of 56 studies reached it within 57 months; a quarter within 32 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitaire Ziekenhuizen KU Leuven →